Parexel, a Privately Owned company headquartered in the US, was founded in 1982 and employs approximately 19,050 individuals. Functioning as a clinical research organization (CRO), it specializes in contract research, consulting, medical communications, and technology solutions. The company serves the worldwide pharmaceutical, biotechnology, and medical device industries, providing a range of Phase I to IV clinical development services. Its global professionals collaborate with biopharmaceutical organizations, innovators, and sites to design and deliver clinical trials, leveraging clinical, regulatory, and therapeutic expertise with a focus on advancing clinical research and making the clinical trial process efficient.
Parexel plans to expand its India workforce from more than 6,000 employees to approximately 8,000 over the next three years, as the country takes on a larger role in global clinical research, patient safety pharmacovigilance, and technology-led drug development, the company stated on August 7, 2026. This follows an agreement on July 31, 2026, where Parexel International (IRL) Limited partnered with PolTREG S.A. to support the preparation and submission of PolTREG’s Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for PTG-007, a Treg cell therapy for type 1 diabetes.
Subscribe for full access to Parexel's products in full detail 
